NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis $20.09 -0.26 (-1.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$20.09▼$21.5050-Day Range$15.45▼$21.8152-Week Range$10.38▼$22.20Volume174,181 shsAverage Volume142,322 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$23.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tyra Biosciences alerts: Email Address Tyra Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside17.0% Upside$23.50 Price TargetShort InterestBearish8.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 4 Articles This WeekInsider TradingSelling Shares$74,040 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.71) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector854th out of 936 stocksPharmaceutical Preparations Industry399th out of 436 stocks 2.4 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTyra Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Tyra Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.31% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 3.0 News and Social Media Coverage News SentimentTyra Biosciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tyra Biosciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for TYRA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Tyra Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,040.00 in company stock.Percentage Held by Insiders15.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tyra Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.71) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tyra Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Tyra Biosciences Stock (NASDAQ:TYRA)Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Read More TYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TYRA Stock News HeadlinesJuly 22, 2024 | seekingalpha.comLots Of Bullish Signals, But No Revenue Or Earnings From Tyra BiosciencesJuly 21, 2024 | msn.comVirginia General Assembly repeals VMSDEP language, veterans say it’s a ‘slight relief’July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 2, 2024 | prnewswire.comTyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)May 23, 2024 | prnewswire.comTyra Biosciences to Present at Upcoming Investor ConferencesMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: TYRA-300’s Progress and Potent FGFR3 Inhibition Signal Promising Outcomes for Tyra BioscienceMay 11, 2024 | markets.businessinsider.comBuy Rating for Tyra Bioscience Amid Promising TYRA-300 Developments and Strong FinancialsMay 10, 2024 | investorplace.comTYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | prnewswire.comTyra Biosciences Reports First Quarter 2024 Financial Results and HighlightsMay 7, 2024 | prnewswire.comTyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S.March 26, 2024 | markets.businessinsider.comTyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug DevelopmentMarch 19, 2024 | msn.comTYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023March 19, 2024 | finance.yahoo.comTyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline ProgressMarch 19, 2024 | msn.comTyra Biosciences files to sell 15.37M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and HighlightsMarch 6, 2024 | finance.yahoo.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 SharesMarch 1, 2024 | finance.yahoo.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 SharesSee More Headlines Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$23.50 High Stock Price Target$28.00 Low Stock Price Target$15.00 Potential Upside/Downside+15.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.61% Return on Assets-26.97% Debt Debt-to-Equity RatioN/A Current Ratio44.83 Quick Ratio44.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book4.29Miscellaneous Outstanding Shares52,540,000Free Float44,449,000Market Cap$1.07 billion OptionableOptionable Beta1.01 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Todd Harris Ph.D. (Age 45)Co-Founder, President, CEO, Secretary, Treasurer & Director Comp: $1.07MMr. Alan Fuhrman (Age 67)Chief Financial Officer Comp: $763.09kDr. Hiroomi Tada M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $816.31kMr. Daniel Bensen (Age 48)Co-Founder & COO Comp: $630.8kDr. Robert L. Hudkins Ph.D. (Age 68)Chief Technology Officer Dr. Ronald V. Swanson Ph.D. (Age 60)Chief Scientific Officer Comp: $536.19kMr. Ali D. Fawaz J.D.General CounselMs. Sarah HonigVice President of Corporate Development & StrategyDr. Piyush R. Patel Ph.D. (Age 58)Chief Development Officer Amy ConradInvestor ContactMore ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNACrinetics PharmaceuticalsNASDAQ:CRNXAlkermesNASDAQ:ALKSAxsome TherapeuticsNASDAQ:AXSMView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 14,352 shares on 7/26/2024Ownership: 0.111%Daniel BensenSold 3,502 sharesTotal: $70,040.00 ($20.00/share)Daniel BensenSold 200 sharesTotal: $4,000.00 ($20.00/share)RA Capital Management L.P.Bought 3,180,155 shares on 5/17/2024Ownership: 19.826%BVF Inc. ILBought 1,921,599 shares on 5/16/2024Ownership: 8.872%View All Insider TransactionsView All Institutional Transactions TYRA Stock Analysis - Frequently Asked Questions How have TYRA shares performed this year? Tyra Biosciences' stock was trading at $13.85 at the beginning of the year. Since then, TYRA stock has increased by 45.1% and is now trading at $20.09. View the best growth stocks for 2024 here. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Tyra Biosciences' top institutional shareholders include Bank of New York Mellon Corp (0.11%). Insiders that own company stock include Todd Harris, Daniel Bensen, Mva Investors, Llc and Boxer Capital, Llc. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TYRA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
